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Abstract
Background: Metreleptin, a recombinant methionyl -human -leptin, was approved to treat patients with
generalized lipodystrophy (GL) in February 2014. However, leptin therapy has been associated with the
development of lymphoma. We present a unique case of a patient with prior history of T cell lymphoma in
remission, who was diagnosed with Acquired Generalized Lipodystrophy (AGL) during the following year after a
clinical remission of her lymphoma without receiving leptin therapy.
Case presentation: A 33-year-old woman with a diagnosis of stage IV subcutaneous panniculitis like T-cell
lymphoma in 2011, underwent chemotherapy. Shortly after completion therapy, she had a relapse and required
more chemotherapy with complete response, followed by allogenic stem cell transplant on June 28, 2012. Since
that time, she has been on observation with no evidence of disease recurrence. Subsequent to the treatment, she
was found to have high triglycerides, loss of fat tissue from her entire body and diagnosis of diabetes. Constellation
of these findings led to the diagnosis of AGL in 2013. Her leptin level was low at 3.4 ng/mL (182 pmol/mL). She is
currently not receiving any treatment with Metreleptin for her AGL.
Conclusions: Causal association between exogenous leptin therapy and T-cell lymphoma still remains unclear. We
hereby present a case of a young woman who was diagnosed with AGL after going into remission from T-cell
lymphoma and who has never been treated with Metreleptin. Steroid therapy and chemotherapy might have
masked the diagnosis of AGL in this patient. We believe that patients can develop these 2 conditions independent
of each other.
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Background
Lipodystrophy is a rare disorder characterized by select-
ive loss or absence of adipose tissue with leptin defi-
ciency, ectopic lipid deposition, and severe metabolic
abnormalities [1]. Lipodystrophy can be congenital or
acquired and its distribution can be generalized or par-
tial [2–4]. Metreleptin, a recombinant methionyl-
human-leptin, was approved to treat generalized lipody-
strophy in February 2014 [5]. Patients with acquired
generalized lipodystrophy (AGL) present with loss of
adipose tissue, hypertriglyceridemia, severe insulin resist-
ance leading to diabetes and hepatic steatosis [3, 4]. Leptin
therapy will improve many of the metabolic conditions in
patients with AGL [6, 7]. Many patients with AGL have
abnormal immune function and can even develop im-
munologic malignancies such as T-cell lymphoma [8].
Since a few patients with AGL developed T-cell lymph-
omas after being exposed to Metreleptin for some time, the
FDA placed a black box warning to monitor for lymphomas
and immune abnormalities while on Metreleptin even
though a causal association between drug exposure and the
development of the T-cell lymphoma was not established.
In this report, we present a unique case of a patient with
prior history of T cell lymphoma in remission, who was
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diagnosed with AGL during the following year after a clin-
ical remission of her lymphoma. She has never received
Metreleptin therapy. We believe that this report will add to
the evidence that T-cell lymphoma and AGL may develop
in the same patient independent of the use of Metreleptin
or exogenous leptin therapy.
Case presentation
A 33-year-old woman without a significant past medical
history, was diagnosed with stage IV subcutaneous pan-
niculitis like T-cell lymphoma in 2011, complicated by
hemophagocytic lymphohistiocytosis. She completed 6
cycles of CHOEP regimen (cyclophosphamide, doxorubi-
cin, etoposide, vincristine and prednisone) in December
2011. Shortly after completion of the therapy, she re-
lapsed and received multiple salvage regimens including
gemcitabine/oxaliplatin, bexarotene/dexamethasone and
pralatrexate. She was then initiated on ESHAP regimen;
a combination of the chemotherapeutic drugs etoposide,
methylprednisolone, a high-dose cytarabine and cisplatin
in April 2012, achieving complete response; followed by an
allogenic stem cell transplant on June 28, 2012. Since that
time, she has been on observation with no evidence of dis-
ease recurrence. Subsequent to the treatment, she was
found to have high triglycerides (230mg/dL [2.60mmol/L]
(normal range < 150mg/dL [1.69mmol/L]) in 2011, and
613mg/dL [6.93mmol/L] in 2013) and loss of fat tissue
from her entire body with accompanying muscular
prominence. She was also diagnosed with diabetes in
12/2013. Constellation of these findings led to the diag-
nosis of AGL in 2013.
At her visit in our clinic, her BMI was 24.4 kg/m2. Her
leptin level was low at 3.4 ng/mL (182 pmol/mL) (a level
of < 4 ng/mL [215 pmol/mL] is accepted as low for women
with BMI < 25 kg/m2 despite a wider range provided by
some reference labs). Upon obtaining a detailed history,
and reviewing her old pictures, it was confirmed that the
onset of body fat loss occurred prior to her T-cell lymph-
oma diagnosis. She also endorsed complaints of hyperpha-
gia and a marked increase in her appetite. Current clinical
endocrine problems outside of diabetes and dyslipidemia
include increased appetite and hyperphagia, lack of men-
ses and a generalized pain syndrome likely attributable to
small fiber neuropathy due to hypertriglyceridemia [9].
Table 1 summarizes her laboratory findings since the
diagnosis until her last visit in our clinic. Figure 1 panels
a-d show her pictures; before diagnosis (a), at diagnosis of
T-cell lymphoma(b), during chemotherapy (c) and after
chemotherapy (d).
At her most recent visit, she was doing well and is in
remission for T cell Lymphoma. A “fat shadow” [10] rep-
resentation from her DXA scan (panel a) and her new
clinical pictures (panels b-e) are presented in Fig. 2. For
her metabolic complications of her AGL, she is currently
not being treated with Metreleptin and this possibility is
still under discussion. She is on multiple medications to
treat her diabetes, high triglycerides and has been trying
to limit her food intake.
Discussion and conclusions
Several cases of T-cell lymphomas after Metreleptin ex-
posure in patients with AGL have been described and led
to a black box warning for the approval of Metreleptin in
the United States. Over the past several years, there have
been several case reports of AGL patients presenting with
T-cell lymphomas who have never received leptin therapy.
Given the rarity of the AGL, documentation of cases with
T-cell lymphoma in the absence of Metreleptin therapy is
Table 1 Laboratory data from our case
Year Glucose
mg/dL (mmol/L)
A1C
% (mmol/mol)
Triglycerides
mg/dL (mmol/L)
Creatinine
mg/dL (μmol/L)
24-H urine protein
2011 82 (4.55) 230 (2.60) 0.4 (35.4) 0.61a
2012 114 (6.33) 416 (4.70) 0.8 (70.7)
2013 114 (6.33) 6.1 (43) 466 (5.27)
613 (6.93)
1.1 (97.2)
2014 115 (6.38) 6.4 (46) 1027 (11.6)
2577 (29.1)
0.9 (79.6) < 5b
2015 201 (11.2) 5.9 (41)
7.2 (55)
1372 (15.5)
776 (8.77)
1.05 (92.8) 283b
2016 201 (11.2) 6.2 (44)
6.9 (52)
478 (5.40)
1392 (15.7)
3615 (40.9)
1.0 (88.4)
2017 146 (8.10) 1604 (18.1)
740 (8.36)
1.06 (93.7)
2018 103 (5.72) 7.7 (61) 4380 (49.5)
336 (3.80)
1.05 (92.8)
A1C: hemoglobin A1C
aand b: reference range for 24-h urine protein in our lab (0–0.15 g/24 h) and in an outside lab (42–225 mg/24 h), respectively
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quite important to provide the evidence base needed to
provide assurance that Metreleptin is not playing a
causal role in the development of the T-cell lymph-
omas. Our current report describes a unique case of a
patient who developed adult onset AGL (which is quite
rare), and who got diagnosed with the AGL after the remis-
sion of her T-cell lymphoma. It is important to underscore
that this is distinctive than cases of children developing
Fig. 1 Development of Physical Features of Lipodystrophy. Panel (a) shows the patient before the diagnosis of T-cell lymphoma and does not
show convincing evidence for generalized lipodystrophy. Physical transformations are shown in panel (b) during the diagnosis of the T-cell
lymphoma, suggesting that she may have already developed features of lipodystrophy at least around her face and neck. Panel (c) shows her
appearance during chemotherapy and panel (d) is after the chemotherapy. Currently (4 years after the completion of therapy) patient’s
appearance is like the picture as shown in (b) suggesting that the chemotherapy and steroid use temporarily masked the diagnosis of
lipodystrophy and were able to modify the physical appearance
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partial lipodystrophy who have undergone hematopoietic
stem cell transplantation during childhood [11].
Lymphomas, particularly peripheral T-cell lymphomas
(PTCL), have been noted in AGL [12, 13]. Brown et al. re-
ported 5 cases of AGL and lymphoma [12]. The coexistence
of AGL and lymphoma likely relates to an underlying auto-
immune preponderance. Autoimmune diseases can occur
commonly in patients with AGL [8, 12, 14, 15], including
both organ-specific autoimmunity (e.g. type 1 diabetes, auto-
immune hepatitis) and systemic autoimmune diseases
(e.g. juvenile dermatomyositis) [12].
Lymphoma can be considered a systemic feature of
AGL instead of an association with lipodystrophy per se
given that other forms of lipodystrophy have not been
associated with an increased risk of lymphomas [12].
Furthermore, it appears that patients with AGL are at an
increased risk of the development of T-cell lymphomas,
especially (PTCL), which is a heterogeneous and generally
aggressive disorder. It is thought to be related to acquired
lipodystrophy, as a subtype of PTCL localizes to the sub-
cutaneous fat, termed subcutaneous panniculitis-like
T-cell lymphoma. Panniculitis may be the presenting
feature of AGL, as in the patient with AGL and PTCL
reported by Yiannias and colleagues [16]. The clinical
assessment of the potential role of Metreleptin in con-
tributing to development and/or progression of
lymphoma is limited by the lack of long term, con-
trolled studies. Three out of 17 patients with AGL
(18%) developed T-cell lymphoma within the NIH co-
hort [5], an incidence significantly higher than what is
observed in the general population (approximately 2
per 100,000) [17].
Fig. 2 Clinical Examination of Fat Distribution. Panel (a) show the “Fat Shadow” obtained from Dual X-ray Energy absorbtiometry (DXA) scan as
described previously in Reference [10]. The fat shadow shows minimally retained fat around the neck and axilla, but loss of fat in a generalized
fashion though not totally absent from the body. Close-up pictures taken in clinic setting demonstrate fat loss in the face and trunk (b), back (c),
buttock and back of the legs (d), and forearms and legs (e). The absence of fat from the face together with the entire abdomen, trunk and
extremities favor the diagnosis of generalized lipodystrophy as opposed to partial lipodystrophy. Neck fat is preserved, but not excessive. Mons
pubis fat was not increased
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Another interesting case of PTCL subsequently compli-
cated by AGL has been described by Aslam et al. [18].
Misra and Garg proposed three classification types for
AGL based on the etiology and pathological mechanisms:
type 1 represents AGL associated with panniculitis; type 2
represents AGL with accompanying autoimmune diseases,
and type 3 represents idiopathic AGL [8]. Aslam et al. felt
that their patient developed AGL and likely represented
an overlap of both the type 2 and 3 varieties [18]. The
classification of AGL is likely not to be as simple, and
there are newer case reports that may change or challenge
these earlier classifications.
The time course of the development of AGL was inter-
esting in our case. One possibility is that our patient
started to develop AGL while she was going through the
diagnosis of her T cell lymphoma as she had panniculitis
related T-cell lymphoma. Her treatment with chemo-
therapy and steroids may have been a contributing factor
in her clinical presentation. Steroids might have also
masked the features of AGL until the remission of T cell
lymphoma and discontinuation of steroids.
In conclusion, there are several clinical lessons from our
case. First, development of extensive panniculitis in an
adult patient who is losing body fat should raise suspicion
of for both T-cell lymphoma and AGL. These patients
should be vigilantly monitored for the development of
metabolic complications over time. Finally, the association
of T-cell lymphoma with known panniculitis within the
setting of AGL may be expected and is not likely impacted
by Metreleptin therapy.
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